Adding Selumetinib to Docetaxel Doesn ’ t Up PFS in NSCLC

No improvement in progression - free survival for previously treated advanced KRAS - mutant NSCLC
Source: The Doctors Lounge - Oncology - Category: Cancer & Oncology Tags: Oncology, Pathology, Pharmacy, Pulmonology, Journal, Source Type: news